PLA2G7 and cardiovascular disorder: Recently, Lp-PLA2 has been considered as a possible target for the treatment of atherosclerosis, and the selective Lp-PLA2 inhibitor Darapladib has been tested as a possible strategy for the prevention and treatment of cardiovascular disease (24).